Year: 2025
Type: editorial
Abstract: Brad Lewis, MD, of Machaon Diagnostics, discusses the implications of three recent studies on acquired hemophilia, thrombotic thrombocytopenic purpura (TTP), and hereditary hemorrhagic telangiectasia (HHT). A small trial on acquired hemophilia found that emicizumab reduced mortality, while a TTP study suggested that silent cerebral infarctions could be a marker for stroke risk and treatment aims. Finally, a trial on VAD044 for HHT showed promising results in reducing epistaxis and improving hemoglobin levels, marking the potential for the first dedicated therapy for this commonly overlooked bleeding disorder.
Author: Brad Lewis, MD
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W4409003600